-
Ab176596-100μgBersanlimab (anti-ICAM1) (C007B-328605)
Price: $181.37List Price: $201.53Bersanlimab (anti-ICAM1) is a fully human monoclonal antibody that targets intercellular adhesion molecule-1 (ICAM-1 or CD54). Bersanlimab (anti-ICAM1) has anticancer effects.Purity>:95% (SDS-PAGE&:SEC)Endotoxin Level<: 1.0EU/mg. -
Ab176596-10mgBersanlimab (anti-ICAM1) (C007B-328606)
Price: $3,487.68List Price: $3,875.19Bersanlimab (anti-ICAM1) is a fully human monoclonal antibody that targets intercellular adhesion molecule-1 (ICAM-1 or CD54). Bersanlimab (anti-ICAM1) has anticancer effects.Purity>:95% (SDS-PAGE&:SEC)Endotoxin Level<: 1.0EU/mg. -
Ab176596-1mgBersanlimab (anti-ICAM1) (C007B-328607)
Price: $890.15List Price: $989.05Bersanlimab (anti-ICAM1) is a fully human monoclonal antibody that targets intercellular adhesion molecule-1 (ICAM-1 or CD54). Bersanlimab (anti-ICAM1) has anticancer effects.Purity>:95% (SDS-PAGE&:SEC)Endotoxin Level<: 1.0EU/mg. -
Ab176596-5mgBersanlimab (anti-ICAM1) (C007B-328608)
Price: $2,178.58List Price: $2,420.65Bersanlimab (anti-ICAM1) is a fully human monoclonal antibody that targets intercellular adhesion molecule-1 (ICAM-1 or CD54). Bersanlimab (anti-ICAM1) has anticancer effects.Purity>:95% (SDS-PAGE&:SEC)Endotoxin Level<: 1.0EU/mg. -
B126286-100mgBEZ235 (C007B-036642)
Price: $179.83List Price: $199.81BEZ235 (NVP-BEZ235) is a dual ATP-competitive PI3K and mTOR inhibitor for p110α/γ/δ/β and mTOR(p70S6K) with IC50 of 4 nM /5 nM /7 nM /75 nM /6 nM, respectively. Inhibits ATR with IC50 of 21 nM, whileshown to be a poor inhibitor to Akt and PDK1.A -
B126286-1gBEZ235 (C007B-036643)
Price: $656.64List Price: $729.59BEZ235 (NVP-BEZ235) is a dual ATP-competitive PI3K and mTOR inhibitor for p110α/γ/δ/β and mTOR(p70S6K) with IC50 of 4 nM /5 nM /7 nM /75 nM /6 nM, respectively. Inhibits ATR with IC50 of 21 nM, whileshown to be a poor inhibitor to Akt and PDK1.A -
B126286-250mgBEZ235 (C007B-036644)
Price: $329.34List Price: $365.93BEZ235 (NVP-BEZ235) is a dual ATP-competitive PI3K and mTOR inhibitor for p110α/γ/δ/β and mTOR(p70S6K) with IC50 of 4 nM /5 nM /7 nM /75 nM /6 nM, respectively. Inhibits ATR with IC50 of 21 nM, whileshown to be a poor inhibitor to Akt and PDK1.A -
B126286-25mgBEZ235 (C007B-036645)
Price: $61.80List Price: $68.67BEZ235 (NVP-BEZ235) is a dual ATP-competitive PI3K and mTOR inhibitor for p110α/γ/δ/β and mTOR(p70S6K) with IC50 of 4 nM /5 nM /7 nM /75 nM /6 nM, respectively. Inhibits ATR with IC50 of 21 nM, whileshown to be a poor inhibitor to Akt and PDK1.A -
-
41-1989BUSHE CURETTE #2/0 ANG 4.4MM
Price: $426.30List Price: $473.66BUSHE CURETTE #2/0 ANG 4.4MM -
C412007-100μgCamrelizumab (anti-PD-1) (C007B-101626)
Price: $117.52List Price: $130.58InformationCamrelizumab is a potent anti-PD-1 /PD-L1 active molecule that can be used in cancer research, including non-small cell lung cancer, esophageal squamous cell carcinoma, Hodgkin lymphoma, and advanced liver cancer.Purity>:95% -
C412007-5mgCamrelizumab (anti-PD-1) (C007B-101629)
Price: $1,379.07List Price: $1,532.30InformationCamrelizumab is a potent anti-PD-1 /PD-L1 active molecule that can be used in cancer research, including non-small cell lung cancer, esophageal squamous cell carcinoma, Hodgkin lymphoma, and advanced liver cancer.Purity>:95%
Bevacizumab
Browse our curated selection of Bevacizumab from leading global manufacturers. Find research-grade reagents, certified standards, and specialty supplies backed by Cenmed's expert sourcing and technical support.
About Bevacizumab
Cenmed Enterprises provides a comprehensive selection of Bevacizumab products sourced from leading global manufacturers. Our catalog spans research-grade reagents, certified standards, and specialty compounds used across clinical, academic, and industrial laboratories worldwide.
With decades of expertise in laboratory supply distribution, we offer competitive pricing, reliable stock availability, and dedicated technical support. Whether you need small quantities for research or bulk orders for manufacturing, our team is ready to assist with sourcing, compliance documentation, and logistics.



